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Victoria Glasson (VG): Managing Editor of On-
cology and Therapy
Kwok-Leung Cheung (KLC): Professor of
Breast Surgery and Medical Education, Univer-
sity of Nottingham
VG: Hello and welcome to the Adis Podcast
Series. Today, we’re looking at the ASCO 2021
conference and the data released. We are talking
to Professor Kwok-Leung Cheung of the
University of Nottingham. Professor Cheung
will be taking us through his highlights from
the ASCO 2021 conference, specifically focusing
on the data released on hormone receptor-pos-
itive, human epidermal receptor 2-negative
breast cancer.
Thank you so much for joining us today,
Professor Cheung. You are professor of breast
surgery with expertise in primary breast cancer
in older women at the University of Notting-
ham. Can you give us a quick overview of your
role and your research interests?
KLC: Well, thank you very much, Victoria.
My role at the university is on breast cancer
research, and also, I do a little bit of work on
medical education. Clinically, I’m practicing as
a breast surgeon in the UK. For my research, I
have several themes for the program. But the
main one is on, as you said, breast cancer in
older women, which covers tumour biology
according to different ages. Also, we look at the
use of geriatric assessment tools to help opti-
mizing the decision-making process for breast
cancer. I also have involvement in clinical trials
in endocrine and targeted therapies.
VG: Brilliant. Today, you’re going to be
talking to us through your main highlights
from the ASCO 2021 breast cancer data, looking
at HR-positive, HER2-negative data from the
conference. To get us started, what were your
take-home messages from the early breast can-
cer data that was released at the conference?
KLC: For the abstracts presented in ASCO on
early breast cancer, the ER-positive and HER2-
negative ones, I think there are a couple of key
points. One is on the use of genomics to aid de-
escalation of treatment. The other one is on the
use of CDK4/6 inhibitors. Maybe we can start
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with the use of genomics to aid de-escalation of
treatment. There were a couple of abstracts
which were looking at the use of different
genomic tools to see whether they could aid
decision-making on extending adjuvant endo-
crine therapy beyond 5 years.
One was using the Breast Cancer Index, and
the other one was using the 70-gene Mam-
maPrint [1, 2]. These tools were explored in the
context of the NSABP B-42 trial. Unfortunately,
the conclusions for both were a negative one,
not showing any definitive roles by using these
tools. I think genomics may help in this setting,
but I don’t think we are there yet at this point.
Also, we may have to identify the precise assays
to be used in different settings, meaning that,
then, in different settings maybe there are dif-
ferent assays that we need to use.
VG: There is an importance to being able to
stratify beyond high or low risk, and to be able
to see the genomic difference in tumour signa-
tures, and really to start to understand them.
Really, we’re starting to look at taking a step
closer to personalized treatment plans for
patients and personalized therapy, which will
be beneficial for patients if we’re able to
implement them. Would you agree? And the
importance of having personalized medicine—
how will that benefit patients in the future?
KLC: I totally agree with you. The impor-
tance of this from the angle of tumour biology
is that although breast cancer seems to be just
one disease, effectively it isn’t. There are differ-
ences in biology, for example, based on my
research according to age. Also, there are dif-
ferent settings whereby the biology is different.
So therefore, if you just apply your treatments
based on a one-size-fits-all approach, even
within ER-positive and HER2-negative disease,
you are bound to either over-treat or under-treat
a patient. Therefore, using these tools in order
to identify the precise biology that would help
you select treatment is very important. But
unfortunately, we haven’t got that as far as this
conference is concerned.
VG: Thank you. So next, you’re going to talk
us through the use of CDK4/6 inhibitor data in
the adjuvant setting.
KLC: Yes, indeed. As I will talk about this a
bit later on the use of CDK4/6 inhibitors in
metastatic disease, as you know, these com-
pounds have been shown to be very, very useful
when given alongside conventional endocrine
therapies such as an aromatase inhibitor or the
selective ER down-regulator fulvestrant in the
metastatic disease setting. So therefore there has
been a lot of interest in exploring their role in
the adjuvant setting. There were some trials
presented in ASCO this year looking at this
subject, trying to use CDK4/6 inhibitors in the
adjuvant setting alongside endocrine therapy.
There were two abstracts, they were all
applying the concept in more high-risk settings
in order to tease out whether the combination
use of a CDK4/6 inhibitor with an endocrine
therapy could actually produce any additional
benefit. One was the setting whereby patients
had high-risk disease, and so much so that they
needed to receive neoadjuvant chemotherapy.
Then, abemaciclib was used plus endocrine
therapy. Interestingly, it did show a superior
invasive disease-free survival. That on its own
was very, very encouraging. That is based on the
monarchE trial [3].
However, when the same concept was
applied using palbociclib in premenopausal
subgroup, patients in the PENELOPE-B trial,
which, again, was seen to be probably a popu-
lation with high-risk disease, no such benefits
were seen in that study [4]. If you pulled the two
together and considered the subject, so it looks
as though individual CDK4/6 inhibitors are
biochemically different, and we know that.
Maybe they produce different clinical efficacies
in different settings. We probably cannot say at
this point in time that if one CDK4/6 inhibitor
works in one setting it will work in all other
settings.
Therefore, regardless of the individual
agents, we have not yet seen any improvement
in overall survival. For the first trial that I just
mentioned, in monarchE [3], there was
improvement in the invasive disease-free sur-
vival, which was the primary endpoint. How-
ever, there was not yet any evidence of
improvement in overall survival, and given the
fact that there was another CDK inhibitor
which did not show the same thing, we are not
quite ready in that sense. It’s still premature to
conclude that the adjuvant role of this
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compound, or class of compounds, is defini-
tively confirmed at this stage.
VG: Excellent, thank you. What were your
main take-home points now from the meta-
static breast cancer research?
KLC: So for metastatic breast cancer, that’s
very, very interesting. I just finished talking
about the adjuvant use of CDK4/6 inhibitors,
whereby there was one trial showing an
improvement with that combination with
endocrine therapy when compared to endo-
crine therapy alone, but not consistently shown
in another study. However, in metastatic dis-
ease for the same tumour type, ER-positive and
HER2-negative disease, as we already know, all
the existing three commercially available
CDK4/6 inhibitors have been shown to have
significant improvement in terms of progres-
sion-free survival when used in combination
with an endocrine therapy when compared to
using the endocrine therapy alone in metastatic
disease setting.
But this year in ASCO, we got some impor-
tant results from two trials which showed that
there was, in fact, long-term overall survival
benefits. Just to quote that, one trial was
PALOMA-3, which was investigating the use of
palbociclib alongside fulvestrant after prior
endocrine therapy in the metastatic disease
setting [5]. There was a significant improvement
in long term overall survival benefit. The hazard
ratio after a median follow-up of 73.3 months
was 0.806, and the 5-year survival of the treat-
ment arm—that means the combination arm—
was 23.3% as compared to 16.8% in the control
arm, which was endocrine therapy alone.
The other trial, MONALEESA-3, which used
ribociclib, another well-known CDK4/6 inhi-
bitor, given alongside fulvestrant, this time as a
first-line endocrine therapy, when compared to
fulvestrant alone also showed similar results [6].
That’s very encouraging in terms of long-term
overall survival benefits. In this trial, what it
showed was a median follow-up of
56.3 months, which was, again, very long term.
So there was a significant benefit in terms of
median overall survival benefits of 53.7 months
versus 41.5 months, with a hazard ratio of 0.73.
With these two studies in mind presented in
ASCO, they are really important, because they
were the first reports of long-term overall sur-
vival benefits. The superiority of this class of
compounds plus endocrine therapy over endo-
crine therapy alone in this setting, which is
metastatic disease, is now definitively con-
firmed, not only with the already known fulfil-
ment of the primary endpoints, which was
progression-free survival, but overall survival
benefits have been shown beyond a number of
years in these two cases, about 5 to 6 years
across two large randomized controlled trials.
VG: Visceral disease in patients with HR-
positive HER2-negative advanced breast cancer
can lead to concerns when it comes to endo-
crine therapy. But the overall survival data that
we’re seeing is starting to show benefits to
patients. Would you agree?
KLC: That’s correct. That was the most
important take-home message or most impor-
tant finding, I would say, in ASCO this year for
this category of tumour types.
VG: Excellent. Would you be able to take us
through CDK4/6 inhibitors and new agents and
the data that was discussed?
KLC: Thank you. Yes, indeed. There was
another trial, which was presented this year,
called DAWNA-1, which investigated a new
CDK4/6 inhibitor called dalpiciclib [7]. That was
used alongside fulvestrant, in a similar concept
to one of the trials that I mentioned before,
after prior endocrine therapy, again, in the
metastatic setting. What it showed was similar
to what we had seen before, a superior pro-
gression-free survival when compared to ful-
vestrant alone. The side effect profile was very,
very similar, and most side effects were man-
ageable like the others, as in the other three
CDK4/6 inhibitors that we saw before. There-
fore, with that in mind, I suggest that this class
of compounds, the CDK4/6 inhibitors, appears
to show consistent benefits when used in com-
bination with endocrine therapy as compared
to endocrine therapy alone.
Now, but the interesting thing would be, or a
clinician would ask, how can I choose between
them? We have got three in the market, and
we’ve got this one coming through in the future
in the pipeline. There might be more. How can
we decide? So if newer compounds under the
same class are to be developed, I think further
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studies may have to be done to tease out indi-
vidual differences in terms of both efficacy and
safety, so clinicians know how to choose
between them. Maybe some of them are more
applicable in certain settings and some in
others.
VG: And the toxicity of CDK4/6 drugs has
been a concern in the past. But would you say
that that’s due to the younger nature of the
treatments, and with further experience of side
effect management and discussing those side
effects with patients, we’ll start to see that
improving?
KLC: I would think so. I think there is no
doubt that the combination of CDK4/6 inhi-
bitor with endocrine therapy give you more side
effects and toxicity when compared to endo-
crine therapy alone. Having said that, all these
studies seem to suggest that the safety profile is
acceptable and the side effects are generally
manageable. So I think the patients have to be
informed about this as a trade-off against an
improved progression-free survival and, now,
with an improved overall survival in a meta-
static disease setting.
VG: Yes. It’s really discussing the importance
of having those conversations with patients, I
think, and allowing them to make an informed
decision about the side effects that they may
experience but the offset benefits that they may
experience as well.
KLC: Definitely, and I think if we go back to
one of the points that you asked very early on
about personalizing treatment and about the
use of genomics, I think one of the potential
things that we could do in the future might be
using genomics or other similar tools to identify
patients whose tumour would behave or would
be controlled equally well with endocrine
therapy alone. So we don’t have to indiscrimi-
nately use a CDK4/6 inhibitor alongside an
endocrine agent, which we know would have
more side effects and toxicities.
VG: Really, really interesting. And then, I
think you’re also going to discuss with us the
use of CDK4/6 inhibitors in older women. So
this is really a topic that’s of a lot of interest to
you.
KLC: Yes, indeed. Indeed. As I just said, it
would be useful on one hand to find out
whether there are situations whereby even in
ER-positive HER2-negative disease whether we
could just use endocrine therapy alone to
achieve similar efficacy outcomes, so that we
don’t have to worry about the side effects.
However, there might be situations whereby the
combination is actually better or definitely
better in certain situations. So therefore, the
study called PALOMA is one of the studies
looking at the use of palbociclib and endocrine
agents.
There is an acronym called PALOMA-AGE or
PALOMAGE, combining the term age with
PALOMA, which actually looked at this subject
in the older population [8]. It wasn’t a ran-
domized controlled trial, but it was using the
concept of combining palbociclib with endo-
crine therapy in a real-world setting. They col-
lected the data in the older population, even in
those above the age of 80. Some of them,
though, had a lot of initial dose reductions,
because it’s real-world data; some clinicians
made their own clinical judgment to reduce the
dose when they started the treatment on those
who were very old, like above the age of 80.
What is showed here was that the study did
show that the safety profile was reasonable and
helped to alleviate concerns of using this class
of compounds in the older population. But
caution remains, especially for those very old or
very frail. Some form of geriatric assessment
should identify who these patients were, the
very frail ones, so that intervention could be
made in order for these treatments to be given—
for example, early dose reduction or initial dose
reduction and/or closer monitoring during the
course of treatments.
VG: In the past we’ve seen discussion on how
difficult it can be to recruit older women into
clinical trials. This is something that you have
written about yourself for the journal [9]. And
older patients make up a small portion of the
clinical trial recruitment. But the number of
older patients living with cancer is increasing,
and they’re definitely underrepresented in
clinical trials. This can have a knock-on effect
onto the knowledge of the compounds that the
older generation would be given. Is this some-
thing that you are starting to see change? Are
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there more older people being included in trial
designs and research from the outset?
KLC: I would say yes and no. Yes, in a sense
that changes are happening because of the joint
efforts of people like myself trying to push this
like a vision. As you know, I have been involved
in the work with the International Society of
Geriatric Oncology. We’ve written a top priori-
ties paper in Lancet Oncology this year [10],
highlighting the importance of research in
older adults with cancer. No, in the sense that
the progress remains slow, and that’s why we’ve
got to keep trying and keep doing. Don’t give
up.
I think it’s important to bear in mind that
trial design could be difficult in the older pop-
ulation. So we need to bear in mind a few pos-
sible solutions or pragmatic solutions.
Something like this one, this abstract, the real-
world data is maybe one of the solutions [8].
Getting randomized controlled trials is one
which would set the foundation to a concept or
clinical concept. Then we’ve got to collect real-
world data in a pragmatic way, especially in the
older population, which could help steer things
as well.
The other thing would be to continue
recruiting patients in a randomized controlled
trial setting, but make sure that there is no
upper limit, for example, where we stratify
patients according to age. Also, another thing
which is important in the geriatric oncology
world is to embed some sort of geriatric assess-
ment into the trial design, so that we don’t have
to worry about someone who is frail, we better
exclude them. Instead, we embed some sort of
geriatric assessment, so that you can actually
include them in a trial setting whereby you
build in some sort of optimization strategies—
for example, in this case, dose reduction or close
monitoring.
VG: It’s a really important point, I think.
Would you agree that it needs the combined
effort of the pharmaceutical companies and the
researchers as well as patient advocacy groups to
really try and inform decisions going forward
into clinical trial designs?
KLC: Indeed. Indeed. And in addition to all
the stakeholders that you have just mentioned,
I would just also like to mention that from the
clinical side, collaboration between the oncol-
ogy world and the geriatric world is also crucial.
VG: Really, really interesting. Well, thank
you so much, Professor Cheung, for that bril-
liant roundup of the data from the ASCO 2021.
We thank you so much for joining us on the
podcast today. We hope that that has been a
really helpful roundup for all of our listeners.
Please look out for other podcasts from the Adis
Journal Podcasts.
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